Sera Prognostics Reports Third Quarter Results
The company reported a net loss and rising PreTRM test volume as it moved from evidence generation to commercial execution.
Updated on Nov. 5, 2026 in Economic Indicators
Sera Prognostics reported financial results for the third quarter ended September 30, 2026. PreTRM test volume increased 54% sequentially, while ordering healthcare providers rose 34%.
Why it matters
The results signal a shift from clinical evidence generation to commercial rollout of a preterm birth test. Florida's Medicaid coverage for PreTRM adds a second state payer pathway for the test.
The figures are company-reported quarterly results: PreTRM test volume rose 54% sequentially and about fivefold from the first quarter of 2026, while the third quarter net loss was $8,053 thousand against $42 thousand in revenue. Whether the anticipated fiscal 2027 volume ramp will follow the same trajectory remains unknown.
The players
Sera Prognostics
A Salt Lake City, Utah-based company developing the PreTRM test to assess the risk of preterm birth.
The details
Sera Prognostics said it has transitioned from evidence generation to commercial execution and scaled its commercial organization to support an expected test volume increase in fiscal 2027. Florida became the second state to provide Medicaid coverage for the PreTRM test, using established fee schedule pricing, and the company is working with its notified body to submit a CE Mark for PreTRM Global in Europe.
Timeline
September 30, 2026: Third quarter ended and balance sheet date.
November 4, 2026: Third quarter financial results announced and conference call held.
Fiscal year 2027: Anticipated test volume ramp and planned pilot initiation.
Economic Context
Preterm birth remains a costly U.S. health problem, with estimated annual prematurity care costs of about $25 billion in 2016, and the March of Dimes gives the United States a D+ grade on preterm birth. Sera Prognostics' commercial push for PreTRM operates within that persistent burden.
For expectant patients in Florida, Medicaid coverage for the PreTRM test may affect whether the test is accessible to them, and the test is assessed in weeks 18 to 21 of pregnancy. Coverage decisions in other states remain unresolved based on the extraction.
The takeaway
Commercial rollout is now the central test for PreTRM, and the coming fiscal year will show whether rising ordering volume translates into sustained revenue. Readers tracking preterm birth care should watch Medicaid coverage decisions in additional states.
What happens next
Sera Prognostics plans to submit the CE Mark for PreTRM Global and anticipates a test volume ramp in fiscal year 2027.
Further reading
Explore more on Economic Indicators to see how company results like these fit into broader state-level economic data.
Source note: This article includes information reported by Mohave Valley Daily News.
